Primary infection with the type 1 human immunodeficiency virus (HIV-1), the etiologic agent of the Acquired Immune Deficiency Syndrome (AIDS), is typically followed by an extended asymptomatic period before the emergence of overt disease. the replication dynamics of HIV-1 throughout this clinical continuum appear critically dependent on the action of specific host trans-regulatory factors that are normally induced in response to immunologic stimuli. In addition to its high affinity for functional enhancer sequences present in the retroviral 5' long terminal repeat (LTR), the NF-kappaB transcription factor is rapidly induced during T cell activation and likely represents a major host regulatory pathway governing the onset of productive HIV-1 expression in persistently infected CD4+ T lymphocytes. Molecular cloning studies have revealed that the 50 kD (p50) and 65 kD (p65) subunits of NF-kappaB both share striking N-terminal sequence homology with the v-Rel oncoprotein, its normal cellular counterpart (c-Rel), and dorsal, a ventral morphogen in Drosophila. In particular, p65 is a potent transcriptional activator of the HIV-1 LTR and also serves as a """"""""receptor"""""""" for IkappaB, a cytoplasmic inhibitor of NF-kappaB function. In sharp contrast, c-Rel acts as a repressor of HIV-1 LTR-directed transcription and may thus correspond to a counter-regulatory host cell factor that promotes viral attenuation. the principal goal of these proposed studies is to explore the physiological regulation, mechanism of action, and biological role of these various Rel polypeptides in the modulation of HIV-1 gene expression. To approach this overall objective, a comprehensive mutational analysis will be undertaken to define and completely dissect the functional domains present in p65 that are required for transactivation, HIV-1 enhancer binding, IkappaB-mediated inhibition, and multimerization. In turn, selected phenotypic variants will be used in an """"""""interaction cloning"""""""" strategy to identify novel NF-kappaB signaling components involved in mediating HIV-1 transcriptional activation or repression via protein/protein interactions. to explore the role of NF- kappaB in transcriptional regulatory mechanisms controlling HIV-1 expression in vivo, monospecific anti-peptide antibodies will be employed to biochemically define the spectrum of Rel polypeptides present in primary CD4+ expressing cells that comprise the principal targets for HIV-1 infection. In conjunction with in vitro transcription and in vivo footprinting analyses, these antibodies will also be used to define the biochemical basis for attenuated HIV-1 expression in established cell culture models of viral latency. Finally, stably transfected human T cell lines will be generated that conditionally express either p65 or c- Rel by fusion to the ligand binding domains of a variety of steroid hormone receptors in order to directly determine their relative transcriptional effects following HIV-1 infection. Together, these proposed experimental approaches should yield fundamental mechanistic insights into two integral components of the NF-kappaB/Rel transcription factor family an their potentially divergent roles in the regulation of HIV-1 gene expression. As such, this information may be key to understanding the precise involvement of NF-kappaB in the transcriptional programs controlling HIV-1 replication in persistently and productively infected cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI033839-01A1
Application #
3148877
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1993-08-01
Project End
1998-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Petro, J B; Rahman, S M; Ballard, D W et al. (2000) Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 191:1745-54
Jo, H; Zhang, R; Zhang, H et al. (2000) NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene 19:841-9
McKinsey, T A; Chu, Z; Tedder, T F et al. (2000) Transcription factor NF-kappaB regulates inducible CD83 gene expression in activated T lymphocytes. Mol Immunol 37:783-8
Connolly, J L; Rodgers, S E; Clarke, P et al. (2000) Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol 74:2981-9
Bash, J; Zong, W X; Banga, S et al. (1999) Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J 18:2803-11
Byrd, V M; Ballard, D W; Miller, G G et al. (1999) Fibroblast growth factor-1 (FGF-1) enhances IL-2 production and nuclear translocation of NF-kappaB in FGF receptor-bearing Jurkat T cells. J Immunol 162:5853-9
Bendall, H H; Sikes, M L; Ballard, D W et al. (1999) An intact NF-kappa B signaling pathway is required for maintenance of mature B cell subsets. Mol Immunol 36:187-95
Hawiger, J; Veach, R A; Liu, X Y et al. (1999) IkappaB kinase complex is an intracellular target for endotoxic lipopolysaccharide in human monocytic cells. Blood 94:1711-6
Chu, Z L; Shin, Y A; Yang, J M et al. (1999) IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1. J Biol Chem 274:15297-300
Chu, Z L; DiDonato, J A; Hawiger, J et al. (1998) The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IkappaB kinases containing IKKalpha and IKKbeta. J Biol Chem 273:15891-4

Showing the most recent 10 out of 19 publications